Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry - PubMed (original) (raw)
Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry
Chi Jen Lee. Biologicals. 2002 Jun.
Abstract
A nephelometric method was used for quantitative analysis of individual polysaccharides (PSs) in a polyvalent pneumococcal conjugate vaccine using CRM(197) as carrier protein. Using this method, the individual types 4, 6B, 9V, 14, 18C, 19F and 23F PSs were found to range between 82.3 to 119% of the manufacturer's indicated values. During conjugation using reductive amination, pneumococcal PS was first oxidized to introduce aldehyde groups. Higher or lower levels of antigen-antibody reaction were observed in periodate activated and then reduced PS of some serotypes compared to non-treated PS. Use of oxidized and reduced PS may provide an early indication of change in conjugation process. Furthermore, since the final monovalent and polyvalent conjugate vaccines gradually change during the storage period, the nephelometry provides an useful analytical method for stability study of these vaccines.
Copyright 2002 The International Association for Biologicals. Published by Elsevier Science Ltd. All rights reserved.
Similar articles
- Studies on vaccine control and immunogenicity of polysaccharides of Streptococcus pneumoniae.
Lee CJ, Lin KT. Lee CJ, et al. Rev Infect Dis. 1981 Mar-Apr;3 Suppl:S51-60. doi: 10.1093/clinids/3.supplement_1.s51. Rev Infect Dis. 1981. PMID: 6169130 Review. - Individual polysaccharide quantification in polyvalent pneumococcal conjugate vaccine using rate nephelometry.
Rajendar B, Pydigummala JS, Rao GS, Chigurambotla R, Matur RV. Rajendar B, et al. J Immunol Methods. 2023 Oct;521:113539. doi: 10.1016/j.jim.2023.113539. Epub 2023 Aug 16. J Immunol Methods. 2023. PMID: 37595680 - Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine.
Sorensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC 3rd, Sacerdote DM, Bradford N, Moore C. Sorensen RU, et al. Pediatr Infect Dis J. 1998 Aug;17(8):685-91. doi: 10.1097/00006454-199808000-00005. Pediatr Infect Dis J. 1998. PMID: 9726341 - Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
Caro-Aguilar I, Indrawati L, Kaufhold RM, Gaunt C, Zhang Y, Nawrocki DK, Giovarelli C, Winters MA, Smith WJ, Heinrichs J, Skinner JM. Caro-Aguilar I, et al. Vaccine. 2017 Feb 7;35(6):865-872. doi: 10.1016/j.vaccine.2016.12.055. Epub 2017 Jan 10. Vaccine. 2017. PMID: 28087148 Review.
Cited by
- Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections.
Poolman JT. Poolman JT. NPJ Vaccines. 2020 Sep 11;5:84. doi: 10.1038/s41541-020-00232-0. eCollection 2020. NPJ Vaccines. 2020. PMID: 32963814 Free PMC article. Review. - Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.
Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L. Poolman J, et al. Clin Vaccine Immunol. 2011 Feb;18(2):327-36. doi: 10.1128/CVI.00402-10. Epub 2010 Dec 1. Clin Vaccine Immunol. 2011. PMID: 21123523 Free PMC article. - Chimeric oligosaccharide conjugate induces opsonic antibodies against Streptococcus pneumoniae serotypes 19A and 19F.
Sanapala SR, Seco BMS, Baek JY, Awan SI, Pereira CL, Seeberger PH. Sanapala SR, et al. Chem Sci. 2020 Jun 26;11(28):7401-7407. doi: 10.1039/d0sc02230f. Chem Sci. 2020. PMID: 34123020 Free PMC article. - Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine.
Deng JZ, Kuster N, Drumheller A, Lin M, Ansbro F, Grozdanovic M, Samuel R, Zhuang P. Deng JZ, et al. NPJ Vaccines. 2023 Jan 23;8(1):2. doi: 10.1038/s41541-022-00584-9. NPJ Vaccines. 2023. PMID: 36690697 Free PMC article. - Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field.
Poolman JT, Wacker M. Poolman JT, et al. J Infect Dis. 2016 Jan 1;213(1):6-13. doi: 10.1093/infdis/jiv429. Epub 2015 Sep 2. J Infect Dis. 2016. PMID: 26333944 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources